IPOpulse
Back to Ticker

Alkem Laboratories Limited

NSE: ALKEM
Healthcare Healthcare
₹5,004
-0.91%EOD · 19 Oct

Alkem Laboratories Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹59,830 Cr
52W Range
₹5934 / ₹5042
Volume
95K
59.8% delivery
1Y Return
-8.9%
P/E Ratio
28.0
P/B Ratio
4.4
ROE
17.6%
Debt / Equity
14.27

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Alkem Laboratories Limited(this stock)₹5,004₹59,830 Cr28.04.417.6%0.39%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
C
41/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityAverage · 53
ValuationAverage · 45
MomentumPoor · 20
High debt load (D/E 14.3)
In confirmed downtrend (Stage 4)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-0.9%
1W
-3.9%
1M
-8.5%
3M
-11.9%
6M
-12.2%
1Y
-8.9%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
35 Neutral
Trend Template
1/7weak
RS vs Nifty (3M)
-5.9pp
Moving Averages (price vs MA)
20-DMA
₹5229
below
50-DMA
₹5285
below
150-DMA
₹5404
below
200-DMA
₹5464
below
From 52W High
-15.7%
From 52W Low
+0.6%
Support (20D)
₹4976
Resistance (20D)
₹5447

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data
ROE Consistency
0/0 years ≥15%
Revenue Growth
+11.0% CAGR
Up 10 of last 11 years
Earnings Quality
Mostly cash-backed
OCF / Net Profit = 0.86x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.